EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real‐world study

Francesca Palandri iD, Monia Marchetti, Elena M Elli, Alessandro Isidori, Ilaria Gianesello, Chiara Sartor, Novella Pugliese iD, Maria Di Perna, Erika Morsia, Susanna Gallo, Federico Itri, Vittorio Montefusco und 30 weitere

Cancer · 15.05.2026 · 132 (10)

DOI: 10.1002/cncr.70457 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 12.05.2026. Verfasst von Francesca Palandri und 41 weiteren Autor:innen. Beteiligte Einrichtung: Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Pyrazoles, Pyrimidines, Primary Myelofibrosis, Benzamides. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Momelotinib, a JAK1 / JAK2 / ACVR1 inhibitor, is approved for treating myelofibrosis with splenomegaly, symptoms, and moderate‐to‐severe anemia. Evidence on its real‐world effectiveness after ruxolitinib failure is limited.

Methods

This study retrospectively analyzed 221 patients who received momelotinib after ruxolitinib failure by assessing spleen, symptom, and anemia responses, safety, and survival. Logistic regression analyses identified the responses’ predictors.

Results

Before momelotinib initiation, all patients had received ruxolitinib for a median of 31.5 months and discontinued as a result of resistance (29.9%), intolerance (48.0%), or both (22.1%). At baseline, all patients started at full dose; 97.3% presented with cytopenia, 34.8% presented with large splenomegaly, and 43.9% were highly symptomatic. Most patients (74.7%) switched from ruxolitinib stop to momelotinib within 2 months without tapering, whereas 18.1% waited over a year. After a median exposure of 8.2 months, adverse events occurred in 35.7% of patients, which prompted dose reductions or permanent discontinuation in 12.7% and 19.9% of cases, respectively. At 6 months, 30.0% achieved ≥50% spleen length reduction (SR50), with higher responses in those with prior SR50 to ruxolitinib and shorter transition intervals. Symptom and anemia responses occurred in 39.2% and 63.4% of cases, respectively. After a median follow‐up of 10.3 months, 11 patients (5.0%) progressed to blast phase, and 37 patients (16.7%) died. Two‐year overall and progression‐free survival (including death and blast phase transformation) were 60.9% and 59.0%, respectively.

Conclusions

Momelotinib demonstrated meaningful clinical benefit and acceptable safety in cytopenic patients pretreated with ruxolitinib, which supports its role after ruxolitinib failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesPyrimidinesPrimary MyelofibrosisBenzamidesHumansNitrilesFemaleRetrospective StudiesMaleAgedMiddle AgedAged, 80 and overTreatment FailureSplenomegaly

Stichwörter der Autor:innen

anemiacytopeniamomelotinibmyelofibrosisthrombocytopenia

Substanzen

NitrilesPyrazolesruxolitinibPyrimidinesmomelotinibBenzamides

Autor:innen und Institutionen

  • Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Hematology and Transplant Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
  • Divisione di Ematologia e Unità Trapianto di Midollo, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
  • Hematology and Stem Cell Transplant Center, AORMN Hospital, Pesaro, Italy.
  • Hematology and Clinical Immunology, Department of Medicine, University of Padua, Padua, Italy.
  • Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.

ORCID-Profile: Francesca Palandri, Novella Pugliese, Giulia Benevolo, Elisabetta Abruzzese, Alessandra Iurlo, Mario Tiribelli, Andrea Duminuco, Massimo Breccia, Andrew T Kuykendall

Förderung

  • Italian Ministry of Health

Zitieren

APA

Palandri, F., Marchetti, M., Elli, E. M., Isidori, A., Gianesello, I., Sartor, C., Pugliese, N., Di Perna, M., Morsia, E., Gallo, S., Itri, F., Montefusco, V., Crisà, E., Biagi, A., Beggiato, E., Mulas, O., Benevolo, G., Abruzzese, E., Santoro, M., …, & Galimberti, S. (2026). Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real‐world study. Cancer, 132(10). https://doi.org/10.1002/cncr.70457

Vancouver

Palandri F, Marchetti M, Elli EM, Isidori A, Gianesello I, Sartor C, et al. Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real‐world study. Cancer. 2026;132(10). doi:10.1002/cncr.70457

BibTeX
@article{Palandri2026,
  author = {Palandri, Francesca and Marchetti, Monia and Elli, Elena M and Isidori, Alessandro and Gianesello, Ilaria and Sartor, Chiara and Pugliese, Novella and Di Perna, Maria and Morsia, Erika and Gallo, Susanna and Itri, Federico and Montefusco, Vittorio and Crisà, Elena and Biagi, Annalisa and Beggiato, Eloise and Mulas, Olga and Benevolo, Giulia and Abruzzese, Elisabetta and Santoro, Marco and Iurlo, Alessandra and Calistri, Elisabetta and Rossi, Marco and Martino, Bruno and Tiribelli, Mario and Fava, Carmen and Dizdari, Arbana and Crugnola, Monica and Duminuco, Andrea and Votto, Amedeo and Guerzoni, Selene and Caocci, Giovanni and Pane, Fabrizio and Lanza, Francesco and Branzanti, Filippo and Dedola, Alessandra and Salvatore, Flavia and Heidel, Florian H and Breccia, Massimo and Palumbo, Giuseppe A and Kuykendall, Andrew T and Lucchesi, Alessandro and Galimberti, Sara},
  title = {Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real‐world study},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {10},
  doi = {10.1002/cncr.70457}
}
Kostenlos starten →